Odonate Therapeutics Inc (NASDAQ:ODT) CEO Kevin C. Tang bought 39,765 shares of the stock in a transaction on Thursday, October 25th. The stock was bought at an average price of $15.35 per share, for a total transaction of $610,392.75. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.
Shares of ODT stock opened at $15.23 on Friday. Odonate Therapeutics Inc has a twelve month low of $14.06 and a twelve month high of $32.00. The company has a market capitalization of $424.68 million and a price-to-earnings ratio of -6.59.
Odonate Therapeutics (NASDAQ:ODT) last announced its earnings results on Tuesday, October 23rd. The company reported ($0.98) earnings per share for the quarter, missing the consensus estimate of ($0.96) by ($0.02). As a group, equities research analysts predict that Odonate Therapeutics Inc will post -3.49 earnings per share for the current fiscal year.
Hedge funds have recently made changes to their positions in the business. Janus Henderson Group PLC lifted its holdings in shares of Odonate Therapeutics by 472.8% in the 2nd quarter. Janus Henderson Group PLC now owns 1,074,348 shares of the company’s stock valued at $23,722,000 after buying an additional 886,794 shares during the period. Bank of New York Mellon Corp lifted its holdings in shares of Odonate Therapeutics by 375.7% in the 2nd quarter. Bank of New York Mellon Corp now owns 81,426 shares of the company’s stock valued at $1,799,000 after buying an additional 64,310 shares during the period. BlackRock Inc. acquired a new stake in shares of Odonate Therapeutics in the 1st quarter valued at approximately $6,018,000. Northern Trust Corp acquired a new stake in shares of Odonate Therapeutics in the 1st quarter valued at approximately $1,489,000. Finally, Alps Advisors Inc. acquired a new stake in shares of Odonate Therapeutics in the 2nd quarter valued at approximately $862,000. Institutional investors own 86.90% of the company’s stock.
Odonate Therapeutics Company Profile
Odonate Therapeutics, Inc, a pharmaceutical company, develops therapeutics for the treatment of cancer. It focuses on the development of tesetaxel, an orally administered chemotherapy agent for patients with advanced or metastatic breast cancer (MBC). Odonate Therapeutics, Inc also conducting a Phase III study in MBC, which is known as CONTESSA.
Featured Article: Market Capitalization – What it Means for Investors
Receive News & Ratings for Odonate Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Odonate Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.